Neupogen

Neupogen Indications/Uses

filgrastim

Manufacturer:

Amgen

Distributor:

Zuellig Pharma
Full Prescribing Info
Indications/Uses
Established cytotoxic chemotherapy: Neupogen is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia (see Special Populations: Pediatric Use under Precautions).
Peripheral blood progenitor cell mobilization (PBPC): Neupogen is indicated for the mobilization of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy and the mobilization of peripheral blood progenitor cells in normal donors (allogeneic PBPC).
Severe Chronic Neutropenia (SCN): Long term administration of Neupogen is indicated in patients, children or adults, with severe congenital, cyclic or idiopathic neutropenia with an Absolute Neutrophil Count (ANC) ≤ 0.5x109/l, and a history of severe or recurrent infections, to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
HIV infection: Neupogen is indicated for the treatment of persistent neutropenia (ANC ≤ 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in